Abivax joins the Nasdaq Biotechnology index

Biotechnology company Abivax has announced its inclusion in the Nasdaq Biotechnology Index, effective before the market opens on December 22, 2025. Listed on Euronext Paris and the Nasdaq, Abivax specializes in developing drugs to stabilize the immune response in patients with chronic inflammatory diseases. Its inclusion in the index reflects the company's significant progress, notably the success of its Phase 3 trials of obefazimod for ulcerative colitis. The Nasdaq Biotechnology Index includes biotechnology and pharmaceutical companies based on strict eligibility criteria such as minimum market capitalization and average daily trading volume.